Arabic Arabic English English French French German German
dark

FUJIFILM Diosynth Biotechnologies and NeuExcell Therapeutics enter manufacturing agreement to rapidly advance NXL-001, a potential neuro-regeneration gene therapy to treat ischemic cortical stroke

The signing of the manufacturing agreement with NeuExcell showcases our flexibility in supporting biotech companies of all sizes, and our focused commitment to enabling NeuExcell to reach the full potential of their innovative gene technology platform on accelerated timelines. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Industry Veteran Rusty Williams Leads Startup to $50 Million Series A

Next Post

Successful demonstration of BioDrone® platform-based drug delivery and confirmed restoration of the myogenic potential of Prokr1-deficient C2C12 myoblasts

Related Posts
Total
0
Share